Agios Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AGIO Nasdaq 2836 www.agios.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agios Pharmaceuticals, Inc.

Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date - Dec 9th, 2025 8:24 am
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Dec 8th, 2025 5:00 am
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Dec 5th, 2025 8:07 pm
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - Dec 3rd, 2025 11:00 am
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - Nov 25th, 2025 6:39 am
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Nov 20th, 2025 10:33 am
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Nov 20th, 2025 10:16 am
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - Nov 19th, 2025 2:20 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Nov 19th, 2025 1:59 pm
Sector Update: Health Care Stocks Mixed in Afternoon Trading - Nov 19th, 2025 11:44 am
Why Shares in Agios Pharmaceuticals Got Crushed Today - Nov 19th, 2025 11:33 am
A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%. - Nov 19th, 2025 9:30 am
Agios Pharmaceuticals (AGIO): Assessing Current Valuation After Strong Revenue Growth and Improved Net Income - Nov 19th, 2025 8:12 am
Traders Await Nvidia Earnings, Fed Minutes, Driving Narrow Premarket Gains for US Equity Futures - Nov 19th, 2025 7:08 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Nvidia Earnings, Fed Meeting Minutes - Nov 19th, 2025 6:29 am
Agios Pharmaceuticals Shares Fall Pre-Bell After Potential Sickle Cell Treatment Fails to Meet Primary Endpoint - Nov 19th, 2025 6:15 am
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease - Nov 19th, 2025 5:00 am
Beta Thalassemia Research Analysis Report 2025-2035: Market Overview and Ecosystem, Epidemiological Analysis, Patent Analysis, Key Trends, Regulatory Landscape, Pipeline Analysis - Nov 18th, 2025 8:32 am
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - Nov 3rd, 2025 7:01 am
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues - Oct 31st, 2025 11:44 am